Entwicklung von dual anvisierenden Antikörper-Derivaten zur Therapie von Neoplasien der B-Zellreihe
Year: 2010
Type: dissertation
Abstract: This study deals with novel single chain Fv Triplebodies (sctb) with the ability to target the tumor cell via two different single chain Fv (scFv). Sctbs are fusion proteins of scFv antibody (ab) fragments, which carry three scFvs in tandem. These sctb were created to achieve a higher selectivity and specificity for antigen (ag) double positive cells by dual-targeting. First two new sctbs, HLA-DR-ds16-hu19 and HLA-DR-ds16-HLA-DR, were constructed and characterized. The scFv components were specific for the human histocompatibility protein HLA-DR; CD16, the low affinity Fc-receptor FcRIII; and CD19 a transmembrane protein on normal and malignant B-lymphoid cells. For comparison, a bispecific scFv (bsscFv), hu19-ds16 and a bsscFv HLA-DR-ds16 were designed. It was shown that sctbs can bind simultaneously with both distal scFvs to antigens (ags) present on the same cancer cell and recruit CD16 positive effector cells for tumor cell lysis. Thereby they can achieve dual-targeting, i.e. connection of two different surface ags on the same cell. Dual-targeting sctbs had been predicted to be capable of eliminating ag double-positive cells preferentially over single-positive cells. In antibody-dependent cellular cytotoxicity (ADCC) experiments with mononuclear cells (MNCs) as effectors, the dual-targeting sctb HLA-DR-ds16-hu19 promoted lysis of Raji cells, an ag double-positive cell-line, at 130-fold lower concentration than the bsscFv hu19-ds16. That indicates that both distal scFvs of the sctb contributed to tumor cell lysis. To test the predication of preferential lysis, a panel of stably transfected HEK 293 cell-lines was generated including CD19 and HLA-DR single- and double-positive cell-lines. When a HLA-DR single-positive and a HLA-DR and CD19 double-positive cell-line with similar surface densities were mixed in equal numbers, the dual-targeting sctb achieved preferential elimination of the double- over the single-positive cells in ADCC experiments. In the second part a sctb 33-ds16-ds19 was produced and tested. It carried two distal scFvs specific for the lymphoid ag CD19 and the myeloid ag CD33, flanking a central scFv specific for the trigger molecule CD16 present on NK cells and macrophages. The unique combination of ags is present on blasts of acute leukemias with mixed lineage phenotype, but not on normal hematopoietic cells. Two available bsscFvs, ds19-ds16 and 33-ds16, with monovalent binding to CD19 and CD33, respectively, were studied in comparison. The sctb 33-ds16-ds19 specifically interacted with all three ags carried on single-positive cells. On the ag double-positive BV-173, the sctb bound with 2-fold greater avidity than bsscFv ds19-ds16 (KD = 21.5 vs. 42.4 nM) and with 1.4-fold greater avidity than bsscFv 33-ds16 (KD = 29 nM). All three fusion proteins had comparable affinity for CD16 and sufficient thermic stability in human serum for therapeutic applications. In ADCC reactions with MNCs as effectors, the sctb promoted lysis of BV-173 at 23-fold lower concentrations than bsscFv ds19-ds16 and at 1.4-fold lower concentration than bsscFv 33-ds16. The sctb mediated potent ADCC of the ag double-positive mixed lineage leukemia cell-line SEM, and the half-maximal effective concentration EC50 for BV-173 cells was 7 pM. The findings of the present study are that the ags do not segregate into separate mem-brane domains of target cells, so that they could not be connected by a single molecule of the dual-targeting sctb. Therefore, the membranes of these cell-lines permit sufficiently effective lateral diffusion and intermingling of these antigens to allow effective ADCC by the sctbs in conjunction with NK cells. Additionally, dual-targeting sctbs permit a degree of selective targeting of double-positive cells, and therefore this novel molecular format opens up attractive perspectives for the future design of new agents.
Author: Schubert, Ingo A. 1977-
Institution: Friedrich-Alexander-Universität Erlangen-Nürnberg
Language: German
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Award: G2786764237
OpenAlex ID: W6990953881
